Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Dabuzalgron

Catalog No. T10952Cas No. 219311-44-1
Alias Ro 115-1240

Dabuzalgron (Ro 115-1240), an orally active selective alpha-1A adrenergic receptor agonist, is used to treat urinary incontinence and prevents doxorubicin-induced cardiotoxicity by maintaining mitochondrial function.

Dabuzalgron

Dabuzalgron

Purity: 98.47%
Catalog No. T10952Alias Ro 115-1240Cas No. 219311-44-1
Dabuzalgron (Ro 115-1240), an orally active selective alpha-1A adrenergic receptor agonist, is used to treat urinary incontinence and prevents doxorubicin-induced cardiotoxicity by maintaining mitochondrial function.
Pack SizePriceAvailabilityQuantity
1 mg$53In Stock
5 mg$126In Stock
10 mg$228In Stock
25 mg$370In Stock
50 mg$555In Stock
100 mg$798In Stock
1 mL x 10 mM (in DMSO)$139In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Dabuzalgron"

Select Batch
Purity:98.47%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Dabuzalgron (Ro 115-1240), an orally active selective alpha-1A adrenergic receptor agonist, is used to treat urinary incontinence and prevents doxorubicin-induced cardiotoxicity by maintaining mitochondrial function.
In vitro
Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM. ERK1 / 2 activation helps Dabuzaron's cardioprotection. Dabuzaron (10 μM; 4 hours) protects NRVM from cell death caused by doxorubicin (DOX). Dabuzaren (10 μM; 4 hours) activation of α1A-AR alleviates the harmful effects of DOX on mitochondrial membrane potential and eliminates the activation of important elements of the apoptotic response to mitochondrial damage.
In vivo
Dabuzaron (10μg / kg; oral tube; twice daily; 7 consecutive days; C57B16J wild-type or α1A-AR gene knockout mice) treatment can prevent DOX cardiotoxicity by activating α1A-AR. Dabuzaron prevents mitochondrial function-related transcript reduction, up-regulates PGC1α, retains ATP content, and reduces oxidative stress in DOX-treated mouse hearts.
AliasRo 115-1240
Chemical Properties
Molecular Weight317.79
FormulaC12H16ClN3O3S
Cas No.219311-44-1
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 25 mg/mL (78.67 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.1467 mL15.7337 mL31.4673 mL157.3366 mL
5 mM0.6293 mL3.1467 mL6.2935 mL31.4673 mL
10 mM0.3147 mL1.5734 mL3.1467 mL15.7337 mL
20 mM0.1573 mL0.7867 mL1.5734 mL7.8668 mL
50 mM0.0629 mL0.3147 mL0.6293 mL3.1467 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Dabuzalgron | purchase Dabuzalgron | Dabuzalgron cost | order Dabuzalgron | Dabuzalgron chemical structure | Dabuzalgron in vivo | Dabuzalgron in vitro | Dabuzalgron formula | Dabuzalgron molecular weight